Skip to content
value.today

Galera Therapeutics, Inc.

🇺🇸 Malvern, Pennsylvania, USAPharmaceuticalsFounded 2012
Total raised
$138 M
5 rounds on record
Latest round
$70 M
Aug 2018
First round on record
Nov 2012
Today
Private
No later event on record

Funding rounds

5 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Galera Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2024$3 MIssued in a merger or acquisition$2 to $10 million

Galera Therapeutics, Inc.: Private sale, Dec 2024

Investors in this round

8 investors had bought by the notice of Jan 14, 2025: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Galera Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • J. Mel Sorensen · Executive Officer, Director
  • Joel Mel Sussman · Executive Officer
  • Kevin R. Lokay · Director
  • Lawrence Mel Alleva · Director
  • Michael R. Friedman · Director
  • Nancy T. Chang · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “Issued in connection with merger transaction between Galera Therapeutics, Inc. and Nova Pharmaceuticals, Inc., as further disclosed in a current report on Form 8-K filed on December 31, 2024.”

Signed by J. Mel Sorensen, M.D., President & Chief Executive Officer. Newest notice filed Jan 14, 2025 (1 amendment). Read the notice at the SEC.

equity, optionsSEC
Aug 2018$70 MNo. 5$50 to $250 million

Galera Therapeutics, Inc.: Raise no. 5, Aug 2018

Investors in this round

23 investors had bought by the notice of Sep 17, 2018: 23 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Galera Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$70 M of $70 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arthur T. Fratamico · Executive Officer
  • Dennis P. Riley · Executive Officer
  • J. Mel Sorensen · Executive Officer, Director
  • Joel A. Sussman · Executive Officer
  • Jon T. Holmlund · Executive Officer
  • Robert A. Beardsley · Executive Officer, Director
  • Stephen T. Ross · Executive Officer
  • Campbell A. Murray · Director
  • Michael A. Powell · Director
  • Michal A. Silverberg · Director
  • Thomas A. Dyrberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mel Sorensen, President & Chief Executive Officer. Newest notice filed Sep 17, 2018. Read the notice at the SEC.

equitySEC
Nov 2016$15 MNo. 4$10 to $50 million

Galera Therapeutics, Inc.: Raise no. 4, Nov 2016

Investors in this round

1 investor had bought by the notice of Nov 28, 2016: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Galera Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis P. Riley · Executive Officer
  • J. Mel Sorensen · Executive Officer, Director
  • Joel A. Sussman · Executive Officer
  • Jon T. Holmlund · Executive Officer
  • Robert A. Beardsley · Executive Officer, Director
  • Campbell T. Murray · Director
  • Frank T. Torti · Director
  • Henry T. Skinner · Director
  • James T. Barrett · Director
  • Thomas T. Dyrberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by J. Mel Sorensen, Chief Executive Officer. Newest notice filed Nov 28, 2016. Read the notice at the SEC.

equitySEC
Oct 2015$37 MNo. 3$10 to $50 million

Galera Therapeutics, Inc.: Raise no. 3, Oct 2015

Investors in this round

7 investors had bought by the notice of Oct 14, 2015: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Galera Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$37 M of $37 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis P. Riley · Executive Officer
  • Jeffery L. Keene · Executive Officer
  • Joel A. Sussman · Executive Officer
  • Jon T. Holmlund · Executive Officer
  • Mel Sorensen · Executive Officer, Director
  • Robert A. Beardsley · Executive Officer, Director
  • Campbell A. Murray · Director
  • Frank A. Torti · Director
  • Henry A. Skinner · Director
  • James A. Barrett · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by J. Mel Sorensen, Chief Executive Officer. Newest notice filed Oct 14, 2015. Read the notice at the SEC.

equitySEC
Jul 2014$5 MNo. 2$2 to $10 million

Galera Therapeutics, Inc.: Raise no. 2, Jul 2014

Investors in this round

7 investors had bought by the notice of Aug 6, 2014: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Galera Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $9 M offered; $5 M still to sell
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$850,000 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joel A. Sussman · Executive Officer
  • Mel Sorensen · Executive Officer, Director
  • Robert A. Beardsley · Executive Officer, Director
  • Campbell A. Murray · Director
  • Frank A. Torti · Director
  • Henry A. Skinner · Director
  • James A. Barrett · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “The amount listed above represents estimated compensation due to the company's executive officers.”

Signed by J. Mel Sorensen, Chief Executive Officer. Newest notice filed Aug 6, 2014. Read the notice at the SEC.

equitySEC
Nov 2012$11 MNo. 1$10 to $50 million

Galera Therapeutics, Inc.: Raise no. 1, Nov 2012

Investors in this round

4 investors had bought by the notice of Dec 10, 2012: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Galera Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$11 M of $11 M offered
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joel J. Sussman · Executive Officer
  • Mel Sorensen · Executive Officer
  • Robert Beardsley · Executive Officer, Director
  • Eric J. Gulve · Director
  • Robert J. Calcaterra · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Robert Beardsley, Director, Chairman of the Board. Newest notice filed Dec 10, 2012. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Galera Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2025).

    SEC Form D · Jan 2025

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jan 2025

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

1 named in official filings. Open an investor to see everything it has backed.

Investors in Galera Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Emerald Bioventures, LLCVenture capitalnot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2026)SEC Form 3

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Galera Therapeutics, Inc.
NameRoleNamed in
J. Mel SorensenExecutive officerJan 2025
Joel Mel SussmanExecutive officerJan 2025
Arthur T. FratamicoExecutive officerSep 2018
Dennis P. RileyExecutive officerSep 2018
Joel A. SussmanExecutive officerSep 2018
Jon T. HolmlundExecutive officerSep 2018
Robert A. BeardsleyExecutive officerSep 2018
Stephen T. RossExecutive officerSep 2018
Jeffery L. KeeneExecutive officerOct 2015
Mel SorensenExecutive officerOct 2015
Joel J. SussmanExecutive officerDec 2012
Robert BeardsleyExecutive officerDec 2012
J. Mel SorensenDirectorJan 2025
Kevin R. LokayDirectorJan 2025
Lawrence Mel AllevaDirectorJan 2025
Michael R. FriedmanDirectorJan 2025
Nancy T. ChangDirectorJan 2025
Campbell A. MurrayDirectorSep 2018
Michael A. PowellDirectorSep 2018
Michal A. SilverbergDirectorSep 2018
Robert A. BeardsleyDirectorSep 2018
Thomas A. DyrbergDirectorSep 2018
Campbell T. MurrayDirectorNov 2016
Frank T. TortiDirectorNov 2016
Henry T. SkinnerDirectorNov 2016
James T. BarrettDirectorNov 2016
Thomas T. DyrbergDirectorNov 2016
Frank A. TortiDirectorOct 2015
Henry A. SkinnerDirectorOct 2015
James A. BarrettDirectorOct 2015
Mel SorensenDirectorOct 2015
Eric J. GulveDirectorDec 2012
Robert BeardsleyDirectorDec 2012
Robert J. CalcaterraDirectorDec 2012